SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Hindustan Bio Sciences Ltd (532041)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532041 NSE: Pharmaceuticals & Drugs | Small Cap | Hind Bio Science Share Price

₹7.91 0.05 (0.64%)

As on 04-Jun'26 16:59

Hindustan Bio Sciences Ltd (532041)

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 532041 NSE: Pharmaceuticals & Drugs | Small Cap | Hind Bio Science Share Price

₹7.91 0.05 (0.64%)

As on 04-Jun'26 16:59

Key Metrics
Valuation Multiples
Market Cap
₹8 Cr.
Current Price
₹7.9
52-Week Low / High
₹5 / 10
TTM EPS
₹-0.1
TTM Sales
₹0.7 Cr.
Book Value per Share
₹0.8
P/E Ratio
0.00
Lower than its 3-year historical median
Industry PE
46.5
Price to Book (P/B)
9.85
Higher than its 5-year historical median
Price to Sales (P/S)
11.00
Higher than its 5-year historical median
EV/EBITDA
-175.06
Lower than its 5-year historical median
Dividend Yield
0.00%
Profitability Efficiency
Return on Equity (ROE)
11.78%
Outperforms industry median
Return on Capital Employed (ROCE)
2.94%
Underperforms industry median
Return on Assets (ROA)
2.97%
Operating Profit Margin
12.6%
Net Profit Margin
12.38%
Gross Profit Margin
12.1%
Growth Momentum
1-yr vs 3-yr growth
Sales Growth (1 Year)
Slowing versus 3-year growth rate
-22.86%
Operating Profit Growth (1 Year)
-
66.67%
Net Profit Growth (1 Year)
-
66.67%
Asset Quality
Promoter Holding
12.19%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹-1 Cr.
Equity
₹2.1 Cr.
Face Value
₹2
All Time Low / High
₹0.10 / 106.65

Hindustan Bio Sciences stock performance

Key Ratios
mw4me loader

Check Before You Invest

M-Cap below 100cr DeciZen not available

Q.1 Is Hindustan Bio Sciences Ltd a good quality company?
Hindustan Bio Sciences Ltd is a quality company, based on a multi-year financial track record.

This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.

We have analysed the performance of the company on the following:

  • How has it performed on generating Profits?

    By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.

  • How efficiently has it utilized Capital?

    By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.

  • How is it managing its Debt?

    By checking its Debt to Equity and Cash Flow from Operations.

How does Hindustan Bio Sciences Ltd performance compare with that of its Peers?
Q.1 Revenue growth of Hindustan Bio Sciences Ltd vs industry peers?
Hindustan Bio Sciences Ltd revenue CAGR is -16.03%, compared to the industry median CAGR of 5.35%, indicating slower growth and losing its market share.
Q.1 Promoter shareholding and pledge status of Hindustan Bio Sciences Ltd?
Promoters hold 12.19% of the Hindustan Bio Sciences Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Q.1 Stock return of Hindustan Bio Sciences Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 14% based on the current price.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Hindustan Bio Sciences Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % -30.2%-8.4%-49%2.7%2.4%-23.7%-16.7%-1.1%1.7%2.9%-
Value Creation
Index
-3.2-1.6-4.5-0.8-0.8-2.7-2.2-1.1-0.9-0.8-

Growth Parameters

Sales 1.3113.61.910.40.91.10.81
Sales YoY Gr.--19.8%2%245.6%-45.5%-46.9%-58.3%114%14.1%-22.9%-
Adj EPS -0.7-0.5-2.20.10.1-0.9-0.5-00.10.1-0.1
YoY Gr.-NANANA-27.3%-1237.5%NANANA66.7%-
BVPS (₹) 4.74.222.12.21.30.80.70.80.90.8
Adj Net
Profit
-0.7-0.5-2.30.10.1-0.9-0.5-00.10.1-0
Cash Flow from Ops. 0.5-0.2-0.2-1.30.80.8-0.3-0.1-1.40-
Debt/CF from Ops. 2.1-8-6.9-2.63.22.5-6.3-49.3-1.892.4-

CAGR

9 Years 5 Years 3 Years 1 Years
Sales -4.8%-16%23.5%-22.9%
Adj EPS NA4.6%NA66.7%
BVPS-17%-16.7%4.6%12.8%
Share Price 13.5% 16.1% -0.6% -18.9%

Key Financial Parameters

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
-12.7-10.7-71.35.33.7-52.6-49.2-5.37.412-9.5
Op. Profit
Mgn %
-9.8-46-227.93.87-90.3-116.4-3.16.112.610.9
Net Profit
Mgn %
-58.9-48.6-220.73.14.2-90.5-119.4-4.45.512.6-11.1
Debt to
Equity
0.20.30.81.61.21.42.83.33.22.82.8
Working Cap
Days
1,6732,0691,6534591,0011,5432,6881,2191,1341,4990
Cash Conv.
Cycle
93119991052561322131021401980

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales1.261.011.033.561.941.030.430.921.050.81
Operating Expenses + 1.381.483.383.431.811.970.940.950.990.71
Manufacturing Costs0.030.050.040.030.020.010.01000
Material Costs0.860.730.572.891.300.680.240.570.640.49
Employee Cost 0.220.210.160.160.200.190.180.180.090.07
Other Costs 0.280.492.610.350.291.090.510.200.260.15
Operating Profit -0.12-0.47-2.350.130.14-0.94-0.51-0.030.060.10
Operating Profit Margin (%) -9.8%-46.0%-227.0%3.7%7.0%-91.1%-117.0%-3.1%6.1%12.3%
Other Income + 000.090000000
Exceptional Items -1.92000000000
Interest 0.030.0100.010.010.010000
Depreciation 0.010.010.010.010.010.0100.010.010
Profit Before Tax -2.08-0.49-2.270.110.12-0.96-0.51-0.040.050.10
Tax 00000.04-0.0200-0-0
Profit After Tax -2.09-0.49-2.280.110.08-0.94-0.52-0.040.060.10
PAT Margin (%) -165.0%-48.6%-220.0%3.1%4.2%-91.1%-120.0%-4.4%5.5%12.4%
Adjusted EPS (₹)-2.0-0.5-2.20.10.1-0.9-0.5-0.00.10.1
Dividend Payout Ratio (%)0%0%0%0%0%0%0%0%0%0%

Valuation of Hind Bio Science - Standalone

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Analyst's Notes

data not found
No data found!

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 4.824.332.052.162.241.300.790.750.800.90
Share Capital 10.2510.2510.2510.2510.2510.2510.252.052.052.05
Reserves -5.43-5.92-8.20-8.09-8.01-8.95-9.46-1.30-1.25-1.15
Debt +0.941.301.573.372.601.862.172.462.562.51
Long Term Debt0.360.550.762.471.670.731.071.122.562.51
Short Term Debt0.580.750.810.890.931.131.091.3300
Minority Interest0000000000
Trade Payables0.090.210.070.060.660.2900.0600
Others Liabilities -0.01-0-0.010.010.040.020.020.0200
Total Liabilities 5.845.843.685.605.553.482.973.283.373.41

Fixed Assets

Net Fixed Assets +0.070.060.060.060.050.040.040.030.030.03
Gross Block0.530.530.540.540.540.540.550.550.550.55
Accumulated Depreciation0.460.470.480.480.490.500.510.510.520.52
CWIP 0000000000
Investments 0000000000
Inventories000.080.110.3400000
Trade Receivables0.470.470.321.671.360.620.140.450.440.44
Cash Equivalents 0.030.040.020.180.200.020.010.010.040.01
Others Assets 5.275.273.213.573.602.802.792.792.862.93
Total Assets 5.845.843.685.605.553.482.973.283.373.41

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 0.46-0.16-0.23-1.320.820.75-0.34-0.05-1.410.03
PBT -0.16-0.49-2.270.110.12-0.96-0.51-0.040.050.10
Adjustment 0.040.020.010.010.010.040.230.010.010
Changes in Working Capital 0.580.312.03-1.450.711.65-0.06-0.02-1.47-0.07
Tax Paid 0000-0.020.020000
Cash Flow From Investing Activity + -0-0-0-0.0100-0000
Capex -0-0-0-0.0100-0000
Net Investments 0000000000
Others 0000000000
Cash Flow From Financing Activity + -0.630.180.211.50-0.81-0.930.340.051.43-0.05
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing -0.600.190.221.50-0.81-0.930.340.051.43-0.05
Interest Paid -0.02-0.01-0-0000000
Dividend Paid 0000000000
Others 0000000000
Net Cash Flow -0.170.01-0.020.170.01-0.18-0.0100.03-0.02

Financial Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)-35.6-10.74-71.35.223.67-52.96-49.49-5.287.4311.78
ROCE (%)-30.17-8.37-49.032.682.4-23.7-16.66-1.11.742.94
Asset Turnover Ratio0.180.170.220.770.350.230.130.30.320.24
PAT to CFO Conversion(x)N/AN/AN/A-1210.25N/AN/AN/A-23.50.3
Working Capital Days
Receivable Days114.90169.50139.10102285.30350.30318.90116.50155.30198.40
Inventory Days13.20028.109.9042.6000000
Payable Days49.6075.9089.208.10101.70255.50225.2021.2018.900.80

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Hindustan Bio Sciences Ltd FAQs

The current trading price of Hind Bio Science on 04-Jun-2026 16:59 is ₹7.91.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Jun-2026 the market cap of Hind Bio Science stood at ₹8.11 Cr

The latest P/E ratio of Hind Bio Science as of 03-Jun-2026 is 0.00.

The latest P/B ratio of Hind Bio Science as of 03-Jun-2026 is 9.85.

The 52-week high of Hind Bio Science is ₹10.19 and the 52-week low is ₹5.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Hind Bio Science is ₹0.74 ( Cr.) .

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Hindustan Bio Sciences Ltd is a below average quality company.

The key valuation ratios of Hindustan Bio Sciences Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Hindustan Bio Sciences Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

About Hindustan Bio Sciences Ltd

Hindustan Bio Sciences was incorporated in 1991. It is a limited company with a share capital of U.S $2.5 million based in Hyderabad, India. The people at the helm of affairs of the company are associated with pharmaceutical and healthcare sector for over two decades and are having penetrative knowledge of the needs of the sick. Hindustan Biosciences is a new entrant in the field of biopharmaceutical industry for providing quality healthcare for the treatment of life threatening diseases at affordable cost even to the lower income segment of Indian Society.

The company started its activities in the year 2001 and has been identifying potential recombinant DNA based biopharmaceutical products for marketing in India. The company has outsourced the manufacturing activity presently and the owned manufacturing facilities will be established at a latter stage. At present the company is setting up a research and development facility for developing the R DNA based biopharmaceuticals for human consumption. The company has finalized a technical consultation tie-up with CCMB (Centre for Cellular and Molecular Biology).

Products

The company has obtained the approval of Genetic Engineering Approval Committee (GEAC) for import and marketing of Recombinant Human Erythropoietin manufactured by M/s. Shandong Kexing Bioproducts Co., Shandong, China. The protocol submitted by the company to conduct clinical trials has been approved by DCGI (Drug Controller General of India) and ethics committees of concerned Hospitals.

Hindustan Bio Sciences, engages in the import and marketing of recombinant deoxyribonucleic acid products for the treatment of life threatening diseases in India. It markets human erythropoietin manufactured by Shandong Kexing Bioproducts Co.

In 2001 the company entered into an agreement with CDSL, NSDL and Venture Capital & Corporate Investments Ltd (R&T agents) for dematerialization. In 2004 Hindustan Bio bagged GEAC nod recombinant human erythropoietin.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×